Penetration of loracarbef into the maxillary sinus: A pharmacokinetic assessment

Clinical Therapeutics

Volumn 18, Issue 2, 1996, Pages 273-284

  Stenquist, Monica ^a   Olen, Lars ^b   Jannert, Magnus ^c   Näslund, Lars ^d   Zeckel, Michael L ^e  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Lidkoping Hospital   (Sweden)

^c Allmänna Hospital   (Sweden)

^d Section of Rheumatology   (Sweden)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBACEPHEM DERIVATIVE; LIDOCAINE; LORACARBEF; XYLOMETAZOLINE;

ABDOMINAL PAIN; ADULT; ARTICLE; BIOASSAY; BODY FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG PENETRATION; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; MAXILLA SINUSITIS; MAXILLARY SINUS; NAUSEA; ORAL DRUG ADMINISTRATION;

EID: 0029938335     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80008-7     Document Type: Article

References (23)

1. Wald ER. Epidemiology, pathophysiology and etiology of sinusitis. Pediatr Infect Dis J. 1985;4:S51-S54.
2. National Center for Health Statistics. Current estimates from the National Health Interview Survey, United States, 1986. Vital and Health Statistics Series 10, No. 164. Washington, DC: US Government Printing Office; 1987.
3. Department of Health and Social Security. Digest of Health Statistics. London: HMSO; 1971.
4. Nielsen RW. Acute bacterial maxillary sinusitis: Results of U.S. and European comparative therapy trials. Am J Med. 1992;92(Suppl 6A):70S-73S.
5. Sydnor TA Jr, Scheid WM, Gwaltney J Jr, et al. Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis. Ear Nose Throat J. 1992;71: 225-232.
6. Gwaltney JM Jr, Scheid WM, Sande MA, Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: A fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol. 1992;90(3 Pt 2):457-461.
7. Scandinavian Study Group. Loracarbef versus doxycycline in the treatment of acute bacterial maxillary sinusitis. J Antimicrob Chemother. 1993;31:949-961.
8. DeSante KA, Zeckel ML. Pharmacokinetic profile of loracarbef. Am J Med. 1992;92(Suppl 6A):16S-19S.
9. Stenquist M, Lindahl D, Eriksson T, et al. Penetration of loracarbef into maxillary sinus fluid and tonsillary tissue in patients. Presented at the 17th International Conference on Chemotherapy; 1991; Berlin, Germany. Abstract.
10. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988;32:289-297.
11. Doern C. In vitro activity of loracarbef and effects of susceptibility test methods. Am J Med. 1992;92(Suppl 6A):7S-15S.
12. Tripodi MF, Adinolfi LE, Utili R, et al. Influence of subinhibitory concentrations of loracarbef (LY 163892) and daptomycin (LY146032) on bacterial phagocytosis, killing and serum sensitivity. J Antimicrob Chemother. 1990;26:491-501.
13. Kusmiesz H, Shelton S, Brown O, et al. Loracarbef concentrations in middle ear fluid. Antimicrob Agents Chemother. 1990;34:2030-2031.
14. Lepage MC, Trottier S, Bergeron MG. Pharmacokinetics and blister fluid penetration of loracarbef after single and multiple doses. Presented at the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 21-24, 1990; Atlanta, Ga. Abstract 1167.
15. Lees AS, Andrews JM, Wise R. The pharmacokinetics, tissue penetration and in vitro activity of loracarbef, a β-lactam antibiotic of the carbacephem class. J Antimicrob Chemother. 1993;32:853-859.
16. Cooper RDG. Novel β-lactam structures - the carbacephems. In: Page MI, ed. The Chemistry of β-lactams. London: Blackie Academic & Profession; 1992: 272-306.
17. Cherrier P, Tod M, Le Gros V, et al. Cefotiam concentration in the sinus fluid of patients with chronic sinusitis after administration of cefotiam hexetil. Eur J Clin Microbiol Infect Dis. 1993;12: 211-214.
18. Sorri M, Peltomaki E, Jokinen K. Bacampicillin in acute maxillary sinusitis: Concentration in sinus secretion and clinical effect. A randomized, double-blind study of two dosage regimens. Scand J Infect Dis. 1981;13:277-280.
19. Lundberg C, Malborg A-S. Concentration of penicillin V and tetracycline in maxillary sinus secretion after repeated doses. Scand J Infect Dis. 1973;5:126-133.
20. Sudderick RM, Lund VJ, Thomson JP, et al. An evaluation of the penetration of cefuroxime axetil into human paranasal sinus tissue. Rhinology. 1992;30:11-16.
21. Karma P, Pukander J, Penttila M. Azithromycin concentrations in sinus fluid and mucosa after oral administration. Eur J Clin Microbiol Infect Dis. 1991;10: 856-859.
22. Paavolainen M, Kohonen A, Palva T, Renkonen OV. Penetration of erythromycin stearate into maxillary sinus mucosa and secretion in chronic maxillary sinusitis. Acta Oto-Laryngol. 1977;84:292-295.
23. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: Application of drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol. 1990;11:319-326.